MARKET

OMER

OMER

Omeros
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.82
+0.22
+1.41%
After Hours: 15.82 0 0.00% 16:01 09/21 EDT
OPEN
15.60
PREV CLOSE
15.60
HIGH
16.05
LOW
15.60
VOLUME
246.15K
TURNOVER
--
52 WEEK HIGH
23.85
52 WEEK LOW
9.25
MARKET CAP
988.68M
P/E (TTM)
-6.9083
1D
5D
1M
3M
1Y
5Y
Looking Into Omeros's Return On Capital Employed
According to data from Benzinga Pro, during Q2, Omeros's (NASDAQ:OMER) reported sales totaled $28.82 million. Despite a 21.55% increase in earnings, the company posted a loss of $24.02 million.
Benzinga · 1d ago
Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/09 21:35
Omeros: Q2 Earnings Insights
Shares of Omeros (NASDAQ:OMER) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 24.59% year over year to ($0.46), which beat the estimate of ($0.57).
Benzinga · 08/09 20:58
Omeros Q2 EPS $(0.46) Beats $(0.57) Estimate, Sales $28.82M Beat $24.27M Estimate
Omeros (NASDAQ:OMER) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.57) by 19.3 percent. This is a 24.59 percent increase over losses of $(0.61) per share from the same
Benzinga · 08/09 20:37
Omeros EPS beats by $0.09, beats on revenue
Omeros (NASDAQ:OMER): Q2 GAAP EPS of -$0.46 beats by $0.09. Revenue of $28.8M (+112.9% Y/Y) beats by $4.53M. At June 30, 2021, Omeros had cash, cash equivalents and short-term investments
Seekingalpha · 08/09 20:08
Omeros Q2 Loss Narrows on Rising Revenue -- Stock Up 3% After-Hours
MT Newswires · 08/09 17:46
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 2021, after the market closes. Omeros management will host a conference call and we...
Business Wire · 08/03 12:30
Earnings Preview: Omeros (OMER) Q2 Earnings Expected to Decline
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/02 19:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OMER. Analyze the recent business situations of Omeros through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OMER stock price target is 37.43 with a high estimate of 100.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 192
Institutional Holdings: 33.77M
% Owned: 54.03%
Shares Outstanding: 62.50M
TypeInstitutionsShares
Increased
55
1.87M
New
18
641.58K
Decreased
39
4.29M
Sold Out
19
904.65K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.45%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/President/Chief Executive Officer/Director
Gregory Demopulos
Chief Accounting Officer/Vice President - Finance/Treasurer
Michael Jacobsen
Chief Scientific Officer/Vice President
George Gaitanaris
Vice President/General Counsel/Secretary
Peter Cancelmo
Vice President/Director of Human Resources
Peter Williams
Vice President
Christopher Bral
Vice President
Nadia Dac
Vice President
Bruce Meiklejohn
Vice President
Catherine Melfi
Vice President
Tina Quinton
Vice President
J. Steven Whitaker
Vice President - Business Development
Timothy Duffy
Lead Director/Independent Director
Thomas Cable
Director
Peter Demopulos
Independent Director
Ray Aspiri
Independent Director
Thomas Bumol
Independent Director
Arnold Hanish
Independent Director
Leroy Hood
Independent Director
Rajiv Shah
Independent Director
Kurt Zumwalt
No Data
About OMER
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.

Webull offers kinds of Omeros Corporation stock information, including NASDAQ:OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.